Abstract
Objective: We studied cariprazine in therapy of delusions with a therapeutic resistance due to traumatic brain injury randomized, double-blind placebo-controlled study manner. Methods: to traumatic brain injury hundred patients (100 all men) whom we studied were under observation in Mental Health Center of the Ministry of Health of the Republic of Azerbaijan from January 2020 to June 2021. The method of randomization was given by lottery. Each patient was randomized to receive either in agreement of the instruction cariprazine (50 patients) over 5 day in dose 6 mg one times per os in morning after meet for 6 weeks or matched placebo (50 patients) in a double-blind manner. A structured clinical interview, for DSM-5Axis I Disorder, Patient Edition, was used to diagnose according to DSM-5 major or mild neurocognitive disorder due to traumatic brain injury. Result: All patients (50) treated with cariprazine treated participants responded by 6 weeks, versus two of the 50 placebo-treated participants (p<0.001). The most common and problematic side effect in the cariprazine group was not. Conclusion: The authors believe this to be the first double-blind placebo-controlled randomization study to test the efficacy of a cariprazine in the management of in therapy of delusions with a therapeutic resistance due to traumatic brain injury randomized, double-blind placebo-controlled study manner. They need to be replicated in a larger study group.
Highlights
Cariprazine is an antipsychotic of the new generation, which is a particle agonist of dopamine receptors
This was a double-blind, placebo-controlled trial for patients diagnosed with DSM-5 for Delusions with a therapeutic resistance due to traumatic brain injury
Patients were observed at the Mental Health Center of the Ministry of Health of the Republic of Azerbaijan
Summary
Cariprazine (vraylar, reaqilq) is an antipsychotic of the new generation, which is a particle agonist of dopamine receptors. It is believed that D3-receptors play an important role in the modulation of cognitive processes and emotional regulation. These pharmacological properties of the drug determine the intended clinical targets in patients with schizophrenia. The prevalence of traumatic brain injury in the United States, 1.7 million cases occur each year, resulting in 1.4 million emergency department visits, 275,000 hospitalizations, and 52,000 deaths. In the United States, 59% of TBI cases are in men. The most common causes of TBI in the United States are falls, car accidents and headaches. Collisions and head blows during contact sports are increasingly recognized as a source of mild TBIs, as recurrent mild TBIs can lead to cumulative long-term consequences [4]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
